ReviewJMIR cancer2025

Leveraging Patient-Reported Outcome Measures for Optimal Dose Selection in Early Phase Cancer Trials.

Bill Byrom et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.